Medicus Pharma Ltd (MDCX)

$2.54 +0.03 (1.20%)
Market Cap 45.25M
Revenue (ttm) 0.00
Net Income (ttm) -11.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 325,500
Avg Vol 399,258
Day's Range N/A - N/A
Shares Out 17.82M
Stochastic %K 41%
Beta N/A
Analysts Strong Sell
Price Target $22.33

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 540 7515
Address:
300 Conshohocken State Road, Suite 200, Conshohocken, United States
2TrustHim
2TrustHim Oct. 3 at 8:30 PM
$MDCX You Know This Is Going To Move When An Ask Blocker Gets In The WAY!!!
0 · Reply
Condemor
Condemor Oct. 3 at 7:54 PM
$MDCX ma como che, este valoro es una fillo de troyana!!!
0 · Reply
Condemor
Condemor Oct. 3 at 2:54 PM
$MDCX i am in mates
0 · Reply
SuperNovaBank
SuperNovaBank Oct. 3 at 5:27 AM
Top watch: GIPR The intrinsic value for GIPR is pegged at $13.53+ per share 🚀 — compare that to current levels 👀 and you’ll see just how MASSIVELY undervalued this play is. With the strategic alternatives process in motion (Cantor Fitzgerald onboard, potential merger, sale, or recap), the upside potential here is unreal. This isn’t just speculation — the numbers are CLEAR 📊. GIPR is trading at a deep discount to its real worth. Smart money will catch on fast. Don’t sleep on this one. 🚨📈.. $MDCX $ARTW $SMX $UPXI
0 · Reply
inquisitive1
inquisitive1 Oct. 2 at 7:53 PM
$MDCX Is the stock regaining its mojo? Or is it a 1-day anomaly?
0 · Reply
JackRyan55
JackRyan55 Oct. 2 at 6:08 PM
$MDCX They should be working on "printing" injectables with NO needle the way an ink jet printer prints a picture.
0 · Reply
inquisitive1
inquisitive1 Oct. 2 at 5:13 PM
$MDCX NVDA, thanks for posting the informative article.
0 · Reply
razorsedge4343
razorsedge4343 Oct. 2 at 3:20 PM
$MDCX Every time see a Medicus commercial on CNBC I can't help but feel like this is a scam. What other companies are running commercials for investors? Mostly no name mining companies no one's heard of...
1 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 2 at 12:04 PM
$MDCX Excellent article that nails exactly where MDCX stands right now. So if you want to update your MDCX knowledge or get acquainted with MDCX, this is a must read. https://beyondspx.com/quote/MDCX/analysis/medicus-pharma-unlocking-growth-through-microneedle-innovation-and-strategic-pipeline-expansion-nasdaq-mdcx
0 · Reply
inquisitive1
inquisitive1 Oct. 1 at 10:31 PM
$MDCX The stock has lost its mojo since I purchased shares at $2.62 on September 19. Fortunately, my only other individual stock, RR, is doing well since buying at $4.26 on Monday. Any pending news for MDCX?
0 · Reply
Latest News on MDCX
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 5 days ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 10 days ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 10 days ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 16 days ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 26 days ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 4 weeks ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Jul 4, 2025, 9:49 AM EDT - 3 months ago

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 30, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 12, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 9, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Jun 2, 2025, 1:40 PM EDT - 4 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 4 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 22, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

May 12, 2025, 2:20 PM EDT - 5 months ago

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Apr 28, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Apr 21, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Mar 10, 2025, 4:05 PM EDT - 7 months ago

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Mar 6, 2025, 8:30 PM EST - 7 months ago

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Mar 6, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 27, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Feb 11, 2025, 7:41 AM EST - 8 months ago

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Dec 12, 2024, 7:30 AM EST - 10 months ago

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Dec 2, 2024, 7:30 AM EST - 10 months ago

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Nov 18, 2024, 7:30 AM EST - 11 months ago

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Nov 15, 2024, 4:47 PM EST - 11 months ago

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

Nov 13, 2024, 6:45 PM EST - 11 months ago

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

2TrustHim
2TrustHim Oct. 3 at 8:30 PM
$MDCX You Know This Is Going To Move When An Ask Blocker Gets In The WAY!!!
0 · Reply
Condemor
Condemor Oct. 3 at 7:54 PM
$MDCX ma como che, este valoro es una fillo de troyana!!!
0 · Reply
Condemor
Condemor Oct. 3 at 2:54 PM
$MDCX i am in mates
0 · Reply
SuperNovaBank
SuperNovaBank Oct. 3 at 5:27 AM
Top watch: GIPR The intrinsic value for GIPR is pegged at $13.53+ per share 🚀 — compare that to current levels 👀 and you’ll see just how MASSIVELY undervalued this play is. With the strategic alternatives process in motion (Cantor Fitzgerald onboard, potential merger, sale, or recap), the upside potential here is unreal. This isn’t just speculation — the numbers are CLEAR 📊. GIPR is trading at a deep discount to its real worth. Smart money will catch on fast. Don’t sleep on this one. 🚨📈.. $MDCX $ARTW $SMX $UPXI
0 · Reply
inquisitive1
inquisitive1 Oct. 2 at 7:53 PM
$MDCX Is the stock regaining its mojo? Or is it a 1-day anomaly?
0 · Reply
JackRyan55
JackRyan55 Oct. 2 at 6:08 PM
$MDCX They should be working on "printing" injectables with NO needle the way an ink jet printer prints a picture.
0 · Reply
inquisitive1
inquisitive1 Oct. 2 at 5:13 PM
$MDCX NVDA, thanks for posting the informative article.
0 · Reply
razorsedge4343
razorsedge4343 Oct. 2 at 3:20 PM
$MDCX Every time see a Medicus commercial on CNBC I can't help but feel like this is a scam. What other companies are running commercials for investors? Mostly no name mining companies no one's heard of...
1 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 2 at 12:04 PM
$MDCX Excellent article that nails exactly where MDCX stands right now. So if you want to update your MDCX knowledge or get acquainted with MDCX, this is a must read. https://beyondspx.com/quote/MDCX/analysis/medicus-pharma-unlocking-growth-through-microneedle-innovation-and-strategic-pipeline-expansion-nasdaq-mdcx
0 · Reply
inquisitive1
inquisitive1 Oct. 1 at 10:31 PM
$MDCX The stock has lost its mojo since I purchased shares at $2.62 on September 19. Fortunately, my only other individual stock, RR, is doing well since buying at $4.26 on Monday. Any pending news for MDCX?
0 · Reply
Condemor
Condemor Oct. 1 at 8:05 PM
$MDCX nice close, tomorrow more blood
0 · Reply
Condemor
Condemor Oct. 1 at 7:20 PM
$MDCX good performance today
0 · Reply
2TrustHim
2TrustHim Oct. 1 at 4:45 PM
$MDCX $2.89!!!
0 · Reply
bullrider19
bullrider19 Oct. 1 at 2:28 PM
$MDCX #2566
0 · Reply
bullrider19
bullrider19 Oct. 1 at 1:55 PM
$MDCX BUY BUY BUY #15000
0 · Reply
Condemor
Condemor Sep. 30 at 6:58 PM
$MDCX shorted 300k at 2.33
0 · Reply
2TrustHim
2TrustHim Sep. 30 at 1:41 PM
$MDCX They Need To Execute The Plan!!! Spend Little On Trials And Convince Big Pharma To Take It The Rest Of The Way
0 · Reply
Condemor
Condemor Sep. 30 at 1:14 PM
$MDCX somebody wants 1.00$ on this one
0 · Reply
inquisitive1
inquisitive1 Sep. 29 at 8:25 PM
$MDCX Condemor, good performance? Down 5 percent!
1 · Reply
Condemor
Condemor Sep. 29 at 7:50 PM
$MDCX good performance today, ñordoooo
0 · Reply
2TrustHim
2TrustHim Sep. 29 at 2:36 PM
$MDCX how important is an FDA C Meeting - Google Search https://www.google.com/search?q=how+important+is+an+FDA+C+Meeting&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari
0 · Reply
JarvisFlow
JarvisFlow Sep. 29 at 2:22 PM
D. Boral Capital updates rating for Medicus Pharma ( $MDCX ) to Buy, target set at 27.
0 · Reply